[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Centre Georges Francois Leclerc\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":492},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,49,76,106,138,163,188,213,239,268,291,315,345,367,395,419,445,466],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100638163","phase-1-study-evaluating-the-safety-feasibility-and-efficacy-of-odi-2001-vaccine-a-personnalized-immunotherapy-in-patients-with-metastatic-or-locally-advanced-colon-cancer-or-pancreatic-cancer-100638163",false,"NCT07587827","Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer","A Phase 1, Open-label, Dose-escalation and Dose-expansion Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or Locally Advanced Colon Cancer or Pancreatic Cancer","ODI-2001-01","Inclusion Criteria:\n\n* Patient capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol.\n* Male or female of \\> 18 years of age\n* Histologically confirmed diagnosis of metastatic or locally advanced solid tumour: • Colorectal carcinoma with MicroSatellite Stable colorectal carcinoma (MSS) not eligible for surgery or other ablative therapies. • Pancreatic adenocarcinoma not eligible for surgery or other ablative therapies.\n* ECOG performance status 0 or 1\n* Baseline Tumoral evaluation (thoraco-abdomino-pelvic computed tomography) performed before the initiation of the standard first line-chemotherapy with at least one measurable lesion according to RECIST 1.1 criteria that can be accurately assessed at baseline and is suitable for repeated assessment.\n* Eligible to start a standard first line chemotherapy indicated in colorectal cancer (FOLFOX\u002FFOLFIRI\u002FFOLFIRINOX or FOLFOXIRI +\u002F- anti-VEGF\u002FEGF) pancreatic cancer (FOLFIRINOX\u002FNabPaclitaxel-Gemcitabine).\n* Adequate haematological, renal and hepatic laboratory requirements : • Haemoglobin \\> 9.0 g\u002FdL • White Blood Cells (WBC) \\> 2.5x109\u002FL including, absolute neutrophils count (ANC) \\> 1.5x109\u002FL, total lymphocytes count \\> 0.5x109\u002FL • Platelet's count \\> 100x109\u002FL• Serum alkaline phosphatase (PAL) ≤ 3 x ULN in the absence of liver or bone metastases and ≤ 5 x ULN in patients with documented bone or liver metastases• Serum transaminases (alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 x ULN in the absence of liver metastases and ≤ 5 x ULN in case of liver metastases\n\n  • Total bilirubin ≤ 1.5 x ULN• Albumin ≥ 30 g\u002FL • Glomerular Filtration Rate ≥ 50 mL\u002Fmin (according to Modification of the Diet in Renal Disease \\[MDRD\\] formula or Cockroft \\& Gault formula)\n* Adequate cardiac function with QTc \\\u003C 450 msec on baseline ECG, using the Fridericia correction cQTcF formula\n* Life expectancy of at least 6 months\n* Patient willing and able to comply with scheduled visits and exams during the follow-up and treatment compliance of the protocol, for the duration of the study including : • mandatory blood sampling (3 blood sampling) • mandatory biopsy of the tumor following enrolment in STEP 1 if no archived material dated less than 2 years is available in sufficient quality or quantity and a mandatory biopsy at 2 months after the initiation of ODI-2001 vaccine administration.\n* Men who are sexually active with women of childbearing potential must agree to use contraceptive method during the ODI-2001 treatment period and for at least 4 months after the last ODI-2001 administration. The individual methods of contraception may be determined in consultation with the investigator and it must have a failure rate of less than 1% per year.\n* A female participant is eligible to participate if she is not pregnant (negative urinary or serum pregnancy test), not breastfeeding, and at least one of the following conditions applies: • Not a woman of childbearing potential OR • Women of childbearing potential who agrees to apply effective contraception method during the treatment period and for at least 4 months after the last dose of study treatment. Effective contraception methods include a combination of any of the following (unless method is abstinence or sterilization, in which only one method is required): - Use of oral, injected, or implanted hormonal methods of contraception, or other forms of hormonal contraception that have comparable efficacy (failure rate \\\u003C 1%). In case of use of oral contraception, women should have been stable on the same pill for a minimum of 6 months before taking study treatment. - Placement of an intrauterine device or intrauterine system. - Barrier methods of contraception: condom or occlusive cap (diaphragm or cervical\u002Fvault caps) with spermicidal foam\u002Fgel\u002Ffilm\u002Fcream\u002Fvaginal suppository. - Total abstinence - Female sterilization at least eight weeks before taking study treatment. - Male sterilization (at least six months prior to screening)\n* Patient must be affiliated to a social health insurance regimen\n\nInclusion criteria for ENROLMENT STEP 1 :\n\nFirst tumoral evaluation shows disease response with the following definition:\n\n* Colorectal carcinoma: A decrease of at least 30% or more in the sum of the diameters of target lesions compared to the initial sum of diameters (Baseline assessment) = at least partial response definition according to RECIST 1.1 definition.\n* Pancreatic carcinoma: A decrease of at least 20% or more in the sum of the diameters of target lesions compared to the initial sum of diameters (Baseline assessment) = adaptative RECIST 1.1 definition.\n\n  * Availability of tumoral material in sufficient quality and quantity in FFPE to performed dB209 manufacturing (5-10 slides according to tissue surface area) + tumoral microenvironment assessment (10 slides). In case of lack of tumoral material to performed the mandatory 2 analysis, a new biopsy should be organized.\n\nInclusion criteria for ENROLMENT STEP 2\n\n* Second tumoral evaluation shows disease response with the following definition:\n\n  * Colorectal carcinoma: A decrease of at least 30% or more in the sum of the diameters of target lesions compared to the initial sum of diameters (Baseline assessment) = at least partial response definition according to RECIST 1.1 definition.\n  * Pancreatic carcinoma: A decrease of at least 20% or more in the sum of the diameters of target lesions compared to the initial sum of diameters (Baseline assessment) = adaptative RECIST 1.1 definition.\n* Patient eligible for a 6-week chemotherapy break, with the start of maintenance treatment beginning in week 7.\n\nExclusion Criteria:\n\n* Patients with \\>10% hepatic involvement as per investigator\n* Exposure to any investigational agent within 30 days of enrolment.\n* Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\n* History of any second malignancy within 2 years with the exception of malignancies with a negligible risk of metastasis or death (e.g. adequately treated carcinoma-in situ of the breast or the cervix, melanoma-in-situ, prostate cancer with Gleason grade ≤6 and prostate specific antigen within normal range).\n* Known or suspected history of immunosuppression (severe auto-immune or immunodeficiency disease) including history of invasive opportunistic infections (e.g tuberculosis, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystis, aspergillosis) despite infection resolution. Presence or suspicion of active bacterial, fungal or viral infections, or uncontrolled fever\n* Patients with major surgery within 4 weeks from enrolment\n* Previous vaccination (either therapeutic and\u002For prophylactic) against cancer\n* Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, ototoxicity, vitiligo, and the laboratory values defined in the inclusion criteria.\n* Patients under chronic treatment with systemic corticoids or other immunosuppressive drugs (e.g., cyclosporine) unless used at dose levels that are not immunosuppressive (e.g. Prednisone at 10 mg\u002Fday or less or as inhaled steroid at doses used for the treatment of asthma) up to 14 days before pre-enrolment.\n* Is receiving growth factors including, but not limited to, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage-colony stimulating factor (GM-CSF), erythropoietin, etc. within 4 weeks from enrolment\n* Known history of Positive serology for Human Immunodeficiency Virus (HIV) or Hepatitis C Virus (HCV); presence of HBs antigen in the serum\n* History of severe auto-immune or immunodeficiency disease\n* Known allergy to any of the components of ODI-2001 (e.g. egg or gentamycin)\n* Known allergy, or history of serious adverse reaction to vaccines such as anaphylaxis, hives, or respiratory difficulty\n* Planned to receive yellow fever or other live (attenuated) vaccines during the course of the study\n* Recent or active clinically significant infection requiring therapy at the time of first dose\n* Any persistent or unresolved drug-related toxicity following previous treatment\n* Myocardial infarction or stroke within previous 6 months, unstable angina, serious uncontrolled cardiac arrhythmia, history of myocarditis, or congestive heart failure\n* Known symptomatic malignant brain lesion\n* Patients with any serious uncontrolled disease or psychiatric condition that, in the opinion of the Investigator, might interfere with the patient's participation in the trial or interfere with the interpretation of trial results","ALL","18 Years",{"count":20,"type":21},77,"ESTIMATED","INTERVENTIONAL",[24],"PHASE1","This is a phase 1, open-label, multicentric study evaluating the safety, feasibility and efficacy of ODI-2001, a personnalized therapeutic cancer vaccine composed of DNA neoantigen vaccine, Modified Vaccinia virus Ankara (MVA) viral adjuvant and anti-CTLA4 (ipilimumab), in patients with metastatic or locally advanced colorectal or pancreatic cancer. The study includes a dose-escalation phase to determine the maximum tolerated dose (MTD) followed by an expansion phase to evaluate efficacy in terms of progression-free survival",[27,28,29,30],"Metastatic Colorectal Cancer (CRC)","Locally Advanced Colorectal Cancer","Metastatic Pancreatic Cancer","Locally Advanced Pancreatic Cancer",[32,33,34,35],"vaccine","pancreas","colorectal","phase 1","NOT_YET_RECRUITING","2026-05-11",{"date":39,"type":40},"2026-05-14","ACTUAL",{"date":42,"type":21},"2026-11-01",{"date":44,"type":21},"2031-05-01",{"name":46,"class":47},"Centre Georges Francois Leclerc","OTHER",2,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":55,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":58,"briefSummary":60,"conditions":61,"keywords":63,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":75},"100639199","a-study-of-selective-internal-radiation-therapy-for-the-management-of-chemotherapy-induced-thrombocytopenia-with-splenomegaly-in-adult-subjects-with-gastrointestinal-cancer-100639199","NCT07575854","A Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer","A Pilot Feasibility Study of Selective Internal Radiation Therapy for the Management of Chemotherapy-induced Thrombocytopenia With Splenomegaly in Adult Subjects With Gastrointestinal Cancer","SPLENIC-SIRT","Inclusion Criteria:\n\n* Written informed consent prior to performing any protocol-related procedures, including screening evaluations.\n* Adult aged 18 years or above.\n* Metastatic or non-metastatic gastrointestinal cancer (gastric, pancreatic, colorectal…) histologically proven.\n* Splenomegaly validated by Splenic volume greater than or equal to 275 mL on imaging associated with thrombocytopenia (3D volumetry)\n* Ongoing thrombocytopenia with serum platelet count ≤ 80.000 mm³ observed on 2 consecutive biological assessments performed at least 7 days apart and at the latest 1 month apart. The second biological assessments should be dated at the latest 3 days from enrolment.\n* Eastern Cooperative Oncology Group (ECOG) 0-2\n* Life expectancy of greater than 6 months\n* Adequate organ function as defined by the following:\n\n  1. Absolute neutrophil count ≥ 1000\u002Fmm³\n  2. Hemoglobin ≥ 8.0 g\u002FdL\n  3. Creatinine \\\u003C 1.5 × ULN or creatinine clearance ≥ 40mL\u002Fmin (Cockcroft-Gault formula)\n  4. ALAT and ASAT ≤ 5 × ULN\n  5. Prothrombin Rate (PR) \\> 50 % (non-correctable\\*) and Activated Partial Thromboplastin time (APTT) \\\u003C 1,5 second (non-correctable \\*) \\* non-correctable coagulopathy is defined as persistent coagulation abnormalities that cannot be corrected, even with appropriate therapeutic interventions (e.g., coagulation factor concentrates, vitamin K, or other corrective treatments)\n* Women patient of childbearing potential or male patient must agree to have efficient birth control method from inform consent form signature to 3 months after Selective internal radiation therapy (SIRT) procedure.\n\nExclusion Criteria:\n\n* Serum platelet count ≤35 000\u002F mm³.\n* History of prior partial splenic embolization, splenectomy or any significant medical history affecting the spleen including medical history of proven cirrhosis with at least one episode of decompensation in the last 6 months from enrolment.\n* Any non-Chemotherapy-Induced Thrombocytopenia and\u002For Chemotherapy-Induced Thrombocytopenia without splenomegaly (as per example, but not limited to, thrombocytopenia related to bone marrow toxicity)\n* Use of any treatment known to increase platelet count 1 month prior to Baseline.\n* History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically.\n* Contraindications to angiography and selective visceral catheterization (bleeding, diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents).\n* Spleen anatomy and\u002For splenic arterials anatomy and\u002For technical constraints identified during screening test which does not allow safe and\u002For ability to deliver the planned target dose\u002Factivity of TheraSphere\n* Serum platelet count ≤35 000\u002F mm³.\n* History of prior partial splenic embolization, splenectomy or any significant medical history affecting the spleen including medical history of proven cirrhosis with at least one episode of decompensation in the last 6 months from enrolment.\n* Any non-Chemotherapy-Induced Thrombocytopenia and\u002For Chemotherapy-Induced Thrombocytopenia without splenomegaly (as per example, but not limited to, thrombocytopenia related to bone marrow toxicity)\n* Use of any treatment known to increase platelet count 1 month prior to Baseline.\n* History of severe peripheral allergy or intolerance to contrast agents, narcotics, sedatives or atropine that cannot be managed medically.\n* Contraindications to angiography and selective visceral catheterization (bleeding, diathesis or coagulopathy that is not correctable by usual therapy or hemostatic agents).\n* Spleen anatomy and\u002For splenic arterials anatomy and\u002For technical constraints identified during screening test which does not allow safe and\u002For ability to deliver the planned target dose\u002Factivity of TheraSphere\n* History of bleeding disorder attributed to another cause other than thrombocytopenia (e.g., thrombopathy, coagulation disorder, gastric bleeding related to portal hypertension etc..) within 2 months of enrolment and\u002For any active bleeding disorder.\n* Any serious medical condition likely to impede successful completion of the study, such as certain mental disorders, cardiac arrhythmias, uncontrolled congestive heart failure or respiratory disease and any toxicity from a prior treatment incompatible with the performance of the procedure. Comorbidities or Investigator judgement of poor overall health status which may make the patient a poor candidate for locoregional treatment.\n* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from ICF signature to 3 months after SIRT.\n* Person not affiliated or not beneficiary of a social security scheme and\u002For\n* Persons deprived of their liberty by a judicial or administrative decision, persons subject to psychiatric care under articles L. 3212-1 and L. 3213-1 who are not covered by the provisions of Article L. 1121-8 and persons admitted to a health or social establishment for purposes other than research, including:\n\n  * Pregnant, parturient, breast-feeding women\n  * Minors (see also inclusion criterion 1)\n  * Persons receiving psychiatric treatment\n  * Persons admitted to a health or social establishment for purposes other than research\n  * Person of full age under curatorship\n  * Adult subject to a mandate for future protection, a family authorization, or a guardianship measure\n* Any contraindications to perform standard spleen SIRT procedure (for example, but not limited to splenic artery catheterization contraindication; such as patients with vascular abnormalities or bleeding diathesis; contraindications to vaccination, etc.)\n* Patients with persistent coagulation abnormalities in the following scenarios:\n\n  * Severe hepatic disease, where the production of coagulation factors is significantly impaired and cannot be corrected by standard treatments.\n  * Coagulopathy induced by anticoagulants (e.g., direct oral anticoagulants or warfarin), where correction is not possible due to treatment instability or poor response to antidotes.\n  * Severe hemostatic dysfunction, where correction is not achieved despite appropriate intervention to restore coagulation balance.\n* Patients with Tc-99m MAA splenic arterial perfusion scintigraphy shows:\n\n  * any extra splenic uptake that may not be corrected by angiographic techniques. Any visual extra-splenic uptake that cannot be corrected by angiographic techniques.\n  * lung shunt that could result in the delivery of a dose greater than 30 Gy to the lungs",{"count":5,"type":21},[59],"NA","This is a prospective, interventional, open-label, single-arm, multicenter pilot study evaluating the safety, tolerability and maximum tolerated dose (MTD) of splenic Selective Internal Radiation Therapy (SIRT) using TheraSphere in adult patietns with gastrointestinal cancer and chemotherapy-induced thrombocytopenia with splenomegaly",[62],"Gastrointestinal Cancer",[64,65,66,67],"splenomegaly","chemotherapy-induced thromobocytopenia","Splenic Selective Internal Radiation Therapy","TheraSphere",{"date":69,"type":40},"2026-05-13",{"date":71,"type":21},"2026-10-01",{"date":73,"type":21},"2029-04-01",{"name":46,"class":47},4,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":22,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":104,"locationsCount":105},"100373364","exome-analysis-position-in-the-strategy-of-genetic-predisposition-factors-identification-in-early-onset-cancer-100373364","NCT04141462","EXOME Analysis Position in the Strategy of Genetic Predisposition Factors Identification in Early-onset Cancer","EX²TRICAN","Inclusion Criteria:\n\nIndex case:\n\n1. Major or minor patient\n2. Histological or cytological evidence of malignant tumor diagnosis\n3. Patient with cancer before age 40 (or before age 30 for breast cancer).\n4. Absence of anomaly found on the oncogenetic panel tested in the predisposition concerned\n5. Patient affiliated to a social security scheme\n6. Signature of Informed Consent EXTRICAN\n7. Availability of a tumor sample if needed secondary functional studies\n8. Availability of both parents when the trio approach will be necessary in the population 1 (or validation of the indication in CPR in case of non-availability of both parents)\n9. Availability of affected relatives in population 2 (or validation of the indication in SPC in case of non-availability of the related person)\n\nRelated:\n\n1. Major or minor patient\n2. Histological or cytological evidence of the diagnosis of malignant tumor if\n3. Patient affiliated to a social security scheme\n4. Signing informed consent EXTRICAN\n\nExclusion Criteria:\n\nIndex and related case:\n\n1. Refusal of the patient participation\n2. Psychiatric illness and \u002F or condition of the patient compromising the understanding of the information or the realization of the study\n3. Patient under guardianship, curatorship or safeguard of justice\n4. Pregnant woman",{"count":84,"type":21},613,[59],"5 to 10% of cancers are due to the presence of a constitutional genetic alteration. It can be inherited from parents (family form) or by accident, in the first moments of life after fertilization (sporadic form). In both cases, this genetic alteration is constitutional and transmissible to descendants. It is hereditary. When an hereditary early form is suspected, several well-known genes generally involved in genetic predispositions to cancer are found by a technique called \" gene panel \". However, this analysis does not always identify the genetic predisposing factors for cancer. New techniques called \"high-throughput exome sequencing (SHD-E)\", allow more than the analysis of the the gene panel. These analysis allow to identify alterations in other genes that could contribute to the development of cancer. The objective of the Ex²trican study is to show, from patients with early cancer (sporadic or familial form), that this approach to exome sequencing can be effective to identify new genetic risk of cancer, when the first panel analysis of genes is negative.",[88,89],"Cancer","Genetic Predisposition",[91,92,93,94,95],"genetic mutations","early sporadic or familial cancer","gene panel","exome analysis","high-throughput exome sequencing","RECRUITING","2026-04-02",{"date":99,"type":40},"2026-04-03",{"date":101,"type":40},"2019-10-07",{"date":103,"type":21},"2028-04-07",{"name":46,"class":47},6,{"id":107,"slug":108,"hasResults":11,"nctId":109,"briefTitle":110,"officialTitle":111,"acronym":112,"eligibilityCriteria":113,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":114,"targetDuration":4,"studyType":22,"phases":116,"briefSummary":117,"conditions":118,"keywords":120,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":130,"startDateStruct":132,"completionDateStruct":134,"leadSponsor":136,"locationsCount":137},"100624745","a-study-evaluating-the-contribution-of-non-coplanar-beam-arrangement-in-reducing-toxicity-in-radiotherapy-for-upper-aerodigestive-tract-cancers-100624745","NCT07413627","A Study Evaluating the Contribution of Non-Coplanar Beam Arrangement in Reducing Toxicity in Radiotherapy for Upper Aerodigestive Tract Cancers","A Randomized Pilot Study Evaluating the Contribution of Non-Coplanar Beam Arrangement in Reducing Toxicity in Radiotherapy for Upper Aerodigestive Tract Cancers","BaReTox","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Patient diagnosed with non-operated, non-metastatic squamous cell carcinoma of the oral cavity or oropharynx, histologically confirmed, with p16 status determined by immunohistochemistry, and indicated for curative bilateral radiotherapy, with or without concomitant chemotherapy\n* Patient scheduled to receive standard photobiomodulation treatment protocol during radiotherapy\n* ECOG performance status ≤ 2\n* Presence of xerostomia \\\u003C 1 according to CTCAE v6.0 at pre-inclusion\n* Patient able to provide informed consent and capable of complying with study follow-up, including visits for completion of quality of life questionnaires and salivary tests\n* Patient affiliated with a social security system or equivalent\n\nInclusion Criteria (RECOARD 2.0 recommendations) to be confirmed with the information provided by the simulation\u002Fplan treatment CT scan :\n\n\\- Exceedance of a dose constraint for at least one Organ at Risk (OAR) as defined below with a coplanar beam arrangement :\n\n* The average dose delivered to at least one parotid gland must be greater than 26 Grays, and\u002For =\\> 65% of the oral cavity receives a dose greater than 30 Grays, and\u002For\n* The average dose delivered to at least one submandibular gland must be greater than 32 Grays, and\u002For\n* The average dose delivered to the larynx exceeds 43.5 Grays.\n\nExclusion Criteria:\n\n* Other head and neck locations than the oral cavity and oropharynx, and\u002For a surgically treated UADT cancer, and\u002For radiotherapy treatment already started.\n* Histologies other than squamous cell carcinoma\n* Tumors requiring only unilateral irradiation.\n* Non-curative irradiation and\u002For metastatic patient\n* Double tumor localization\n* Previous history of head and neck radiotherapy.\n* Inability to comply with study follow-up visits and medical assessments due to geographical, social, or psychological reasons.\n* Individuals under legal custody or guardianship (including curatorship).\n* Pregnant or breastfeeding women (pregnancy test required at inclusion).",{"count":115,"type":21},70,[59],"Cancers of the upper aerodigestive tract (UADT) are frequently treated with external beam radiotherapy, either alone or in combination with chemotherapy. Despite major advances achieved with intensity-modulated radiotherapy (IMRT\u002FVMAT), irradiation of organs at risk (OARs) remains unavoidable and may lead to acute and late toxicities such as xerostomia, hyposalivation, swallowing disorders, and impaired quality of life. These toxicities are closely related to the dose delivered to salivary glands and other critical structures, and recommended OAR dose constraints are often exceeded to ensure adequate tumor coverage.\n\nNon-coplanar beam arrangements (NCBA) represent a potential strategy to further reduce radiation dose to OARs while maintaining equivalent target coverage. However, their clinical implementation has been limited due to technical complexity and the risk of collisions between the linear accelerator and the patient. The recent implementation of the opto-numerical solution MapRT® (VisionRT), based on three-dimensional modeling of the patient and the linear accelerator, allows safe and reliable identification of feasible non-coplanar beam trajectories. Retrospective dosimetric analyses conducted at our institution have demonstrated significant dose reductions to several OARs in UADT cancer patients treated with NCBA compared with conventional coplanar beam arrangements, without compromising tumor dose coverage.\n\nBaReTox is a prospective, open-label, randomized, single-center pilot trial designed to evaluate the clinical impact of non-coplanar beam radiotherapy on treatment-related toxicities and quality of life in patients with non-operated, non-metastatic squamous cell carcinoma of the oral cavity or oropharynx. Adult patients eligible for curative-intent bilateral radiotherapy, with known HPV (p16) status, are randomized to receive either standard coplanar radiotherapy (control arm) or non-coplanar radiotherapy (experimental arm), with or without concomitant chemotherapy. All patients receive a standard photobiomodulation protocol during radiotherapy.\n\nThe primary objective is to compare the change in head and neck cancer-specific quality of life between baseline and three months after completion of radiotherapy, assessed using the EORTC QLQ-H\\&N35 questionnaire, focusing on swallowing, social eating, and dry mouth domains. Secondary objectives include comparison of acute and late toxicities graded according to CTCAE version 5.0, assessment of salivary function by sialometry, evaluation of global and disease-specific quality of life over time, progression-free survival, feasibility of delivering non-coplanar radiotherapy, dosimetric impact on organs at risk, and evaluation of radiation-induced lymphopenia.\n\nThis pilot study aims to provide clinical proof of concept for the benefit of non-coplanar beam radiotherapy in reducing toxicity and improving quality of life in patients with UADT cancers",[119],"Squamous Cell Carcinoma of the Oral Cavity and Oropharynx",[121,122,123,124,125,126,127,128],"Head and Neck Squamous Cell Carcinoma","Upper Aerodigestive Tract Cancer","Oral Cavity Cancer","Oropharyngeal Cancer","Radiotherapy","Non-Coplanar Beam Radiotherapy","Xerostomia","Intensity-Modulated Radiotherapy","2026-02-16",{"date":131,"type":40},"2026-02-18",{"date":133,"type":21},"2026-04-01",{"date":135,"type":21},"2029-11-01",{"name":46,"class":47},1,{"id":139,"slug":140,"hasResults":11,"nctId":141,"briefTitle":142,"officialTitle":142,"acronym":143,"eligibilityCriteria":144,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":145,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":148,"conditions":149,"keywords":152,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":154,"lastUpdatePostDateStruct":155,"startDateStruct":157,"completionDateStruct":159,"leadSponsor":161,"locationsCount":162},"100621891","predicting-response-to-anti-pd-1pd-l1-immunotherapy-by-plasma-extracellular-vesicle-analysis-100621891","NCT07376512","Predicting Response to Anti-PD-1\u002FPD-L1 Immunotherapy by Plasma Extracellular Vesicle Analysis","EVpredict","Inclusion Criteria:\n\n* Age ≥18 years.\n* Histologically confirmed diagnosis of non-small cell lung cancer (NSCLC) or locally advanced\u002Fmetastatic unresectable melanoma.\n* Patient scheduled to initiate anti-PD-(L)1 therapy, either as monotherapy or in combination (other immune checkpoint inhibitors, chemotherapy, etc.).\n* Baseline tumor assessment performed within 28 days prior to enrollment (CT scan of thorax, abdomen, and pelvis) with at least one measurable lesion according to RECIST 1.1 criteria.\n* Life expectancy \\>6 months.\n* Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 at enrollment.\n* Patient able to provide informed consent and comply with study procedures.\n* Patient covered by a social security system or equivalent.\n\nExclusion Criteria:\n\n* Prior treatment with immunotherapy.\n* Presence of EGFR or ALK mutation (applicable only to the lung cohort).\n* Presence of another synchronous malignancy.\n* Diagnosis of uveal melanoma.\n* Treatment with systemic immunosuppressants, including within 28 days prior to enrollment, or corticosteroids \\>10 mg\u002Fday, including within 14 days prior to enrollment.\n* Disease not measurable according to RECIST 1.1 criteria.\n* Positive serology for HIV, HBV, or HCV.\n* Pregnant or breastfeeding women.\n* Inability to comply with study follow-up and visits for geographic, social, or psychological reasons.\n* Individuals deprived of liberty or under legal guardianship (including curatorship).",{"count":146,"type":21},378,"OBSERVATIONAL","The objective of this prospective multicenter study is to evaluate whether the analysis of immunological biomarkers present in circulating extracellular vesicles is associated with the response to anti-PD-1\u002FPD-L1 treatments in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) or unresectable melanoma.\n\nPatients will receive standard-of-care treatment and will be followed according to routine clinical practice. The study involves the collection of four study-specific blood samples at different time points during follow-up, as well as the collection of standard immunohistochemistry results, thoraco-abdomino-pelvic CT scans, and tumor DNA genotyping analyses performed as part of routine care.\n\nThe study aims to determine:\n\n* whether baseline biomarkers in extracellular vesicles are associated with response to anti-PD-1\u002FPD-L1 treatment,\n* how these biomarkers change over the course of treatment, and\n* to provide exploratory data for the development of predictive immunological response signatures.",[150,151],"Non-Small Cell Lung Cancer","Melanoma (Skin Cancer)",[153],"standard treatment with anti-PD-(L)1 monotherapy or combination therapy","2026-01-22",{"date":156,"type":40},"2026-01-29",{"date":158,"type":21},"2026-03-01",{"date":160,"type":21},"2030-03-01",{"name":46,"class":47},5,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":171,"targetDuration":4,"studyType":22,"phases":173,"briefSummary":175,"conditions":176,"keywords":177,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":180,"lastUpdatePostDateStruct":181,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":137},"100511320","phase-1-clinical-trial-evaluating-the-safety-and-efficacy-of-chemoimmunotherapy-plus-short-course-of-mek-inhibitor-in-first-line-of-treatment-of-metastatic-non-squamous-non-small-cell-lung-adenocarcinoma-with-pdl1--50--100511320","NCT05937906","Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 \u003C 50 %.","Phase Ib\u002FII Clinical Trial Evaluating the Safety and Efficacy of Chemoimmunotherapy Plus Short Course of Mek Inhibitor in First Line of Treatment of Metastatic Non Squamous Non Small Cell Lung Adenocarcinoma With PDL1 \u003C 50 %.","IMMUNOMEK","Inclusion Criteria:\n\n* Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Written informed consent and any locally required authorization obtained from the patient prior to performing any protocol-related procedures, including screening evaluations.\n* Patients must be diagnosed with a metastatic or locally advanced non squamous non-small cell lung cancer\n* Absence of previous treatment for or locally advanced or metastatic non-small cell lung cancer. Previous adjuvant therapy is allowed if \\> 12 months from the last injection\n* Age \\>18 years at time of study entry\n* Performance status ECOG of 0 or 1\n* Life expectancy ≥ 6 months\n* PD-L1\\\u003C50% using TPS scoring\n* At least one lesion measurable as defined by standard imaging criteria for the patient's tumor type (RECIST v1.1) that can be accurately assessed at baseline and is suitable for repeated assessment\n* Body weight \\>30 kg\n* Adequate normal organ and marrow function as defined below:\n* Adequate cardiac function:\n\n(QTc \\\u003C 450 msec on baseline ECG, using the Fridericia correction cQTcF formula) or other clinically significant ventricular or atrial arrhythmia.\n\nLeft ventricular ejection fraction (LVEF) ≥ 50%\n\n* Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up.\n* Patient affiliated to a social security regimen or beneficiary of the same according\n* Validation of the quality and quantity of the tumoral material at inclusion (existing material dated less than one month and\u002For fresh biopsy).\n* Patient is willing to perform the fresh biopsies mandatory for the protocol:\n\nPhase I: A mandatory fresh biopsy of 4 samples at inclusion and after Cycle 2 (betweenC2J7 and C2J14) Phase II: A mandatory fresh biopsy. of 4 samples at inclusion. Second biopsy at 4-5 weeks after treatment initiation is optional.\n\nExclusion Criteria:\n\n* Participation in another clinical study with an investigational product during the last 2 months\n* Concurrent enrolment in another clinical study, unless it is an observational (non-interventional) clinical study or during the follow-up period of an interventional study\n* Presence of EGFR, ROS or ALK targetable mutations\n* Any unresolved toxicity NCI CTCAE Grade ≥2 from previous anticancer therapy with the exception of alopecia, ototoxicity, vitiligo, and the laboratory values defined in the inclusion criteria. Any concurrent chemotherapy, IP, biologic, or hormonal therapy for cancer treatment. Concurrent use of hormonal therapy for non-cancer-related conditions (e.g., hormone replacement therapy) is acceptable before the first dose of study drug\n* Major surgical procedure within 28 days prior to therapy initiation IP. Note: Local surgery of isolated lesions for palliative intent is acceptable. Gastrostomy, ventriculo-peritoneal shunt, endoscopic ventriculostomy, tumor biopsy and insertion of central venous access devices are not considered major surgery, but for these procedures, a 48 hour interval must be maintained before the first dose of study drug\n* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter drug absorption of oral drugs (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea or malabsorption syndrome).\n* History of allogenic organ, bone marrow or double umbilical cord blood transplantation\n* Active or prior documented autoimmune or inflammatory disorders (including inflammatory bowel disease \\[e.g., colitis or Crohn's disease\\], diverticulitis \\[with the exception of diverticulosis\\], systemic lupus erythematosus, Sarcoidosis syndrome, or Wegener syndrome \\[granulomatosis with polyangiitis, Graves' disease, rheumatoid arthritis, hypophysitis, uveitis, etc\\]). The following are exceptions to this criterion:\n\nPatients with vitiligo or alopecia Patients with hypothyroidism (e.g., following Hashimoto syndrome) stable on hormone replacement Any chronic skin condition that does not require systemic therapy Patients without active disease in the last 5 years may be included but only after consultation with the study physician Patients with celiac disease controlled by diet alone\n\n* History of glaucoma, any retinal pathology considered to be a risk factor for central serous retinopathy, retinal vein occlusion (RVO) or neovascular macular degeneration. Also, any risk factors for RVO as intraocular pressure (IOP) \\>21, uncontrolled blood glucose\n* Patients considered a poor medical risk due to a serious, uncontrolled medical disorder, non-malignant systemic disease. Any uncontrolled intercurrent illness, including but not limited to, ongoing or active infection, symptomatic congestive heart failure (including history of myocardial infarction within 3 months, cerebrovascular accident, transient ischemic attack, symptomatic pulmonary embolism, or any cardiac arrhythmias, e.g, ventricular, supraventricular, supraventricular, nodal arrhythmias, or conduction abnormality within 12 months of screening) uncontrolled hypertension, unstable angina pectoris, cardiac arrhythmia, interstitial lung disease, serious chronic gastrointestinal conditions associated with diarrhea, or psychiatric illness\u002Fsocial situations that would limit compliance with study requirement, substantially increase risk of incurring adverse events unstable spinal cord compression, superior vena cava syndrome, extensive interstitial bilateral lung disease on high Resolution Computed Tomography (HRCT) sacan or any psychiatric disorder that prohibits obtaining informed consent.\n* Currently taking medications with known risk of prolonging the QT interval or inducing Torsades de Pointes\n* Resting ECG indicating uncontrolled, potentially reversible cardiac conditions, as judged by the investigator (eg. unstable ischemia, uncontrolled symptomatic arrhythmia, congestive heart failure, cQTcF prolongation \\>450ms, electrolyte disturbances, etc.), or patients with congenital long QT syndrome\n* Patients with myelodysplastic syndrome\u002Facute myeloid leukaemia or with features suggestive of MDS\u002FAML\n* History of another primary malignancy except for Malignancy treated with curative intent and with no known active disease ≥5 years before the first dose of IP and of low potential risk for recurrence Adequately treated non-melanoma skin cancer or lentigo maligna without evidence of disease Adequately treated carcinoma in situ without evidence of disease\n* History of leptomeningeal carcinomatosis\n* Patient with symptomatic central nervous system (CNS) metastases\n* History of active primary immunodeficiency or Immunocompromised patients e.g, patients who are known to be serologically positive for human immunodeficiency virus (HIV)\n* Active infection including tuberculosis (clinical evaluation that includes clinical history, physical examination and radiographic findings, and TB testing in line with local practice), hepatitis B (known positive HBV surface antigen (HBsAg) result), hepatitis C, or human immunodeficiency virus (positive HIV 1\u002F2 antibodies). Patients with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody \\[anti-HBc\\] and absence of HBsAg) are eligible. Patients positive for hepatitis C (HCV) antibody are eligible only if polymerase chain reaction is negative for HCV RNA.\n* Current or prior use of immunosuppressive medication within 14 days before the first dose of immunotherapy. The following are exceptions to this criterion:\n\nIntranasal, inhaled, topical steroids, or local steroid injections (e.g., intra articular injection) Systemic corticosteroids at physiologic doses not to exceed 10 mg\u002Fday of prednisone or its equivalent Steroids as premedication for hypersensitivity reactions (e.g., CT scan premedication)\n\n* Receipt of live or live attenuated vaccine within 30 days prior to the first dose of IP. Note: Patients, if enrolled, should not receive live vaccine (yellow fever vaccination is forbidden) whilst receiving IP and up to 30 days after the last dose of IP.\n* Female patients who are pregnant or breastfeeding or male or female patients of reproductive potential who are not willing to employ effective birth control from screening to 180 days after the last dose of treatment. (Contraceptive requirements: Male patients must use a condom during treatment and for 3 months after the last dose when having sexual intercourse with a pregnant woman or with a woman of childbearing potential. Female partners of male patients should also use a highly effective form of contraception if they are of childbearing potential.)\n* Known allergy or hypersensitivity to any of the study drugs or any of the study drugs excipients",{"count":172,"type":21},24,[24,174],"PHASE2","Monocentric study composed by 2 steps :\n\n1. First step is a phase I with the aim of establish the recommended dose of mirdametinib administration (2 or 4 mg twice a day for 7 or 14 days per cycle for the 4 first of carboplatin\u002Fpemetrexed\u002Fpembrolizumab treatment)\n2. Second step is a non comparative randomized (2:1) phase II trial testing the recommended dose of mirdametinib administration. The aim is the efficacy and safety of short course of mirdametinib treatment for the 4 first cycles of the carboplatin\u002Fpemetrexed\u002Fpembrolizumab treatment.",[150],[178,179],"locally advanced or metastatic","non squamous non small cell lung cancer","2025-09-29",{"date":182,"type":40},"2025-10-02",{"date":184,"type":40},"2024-07-30",{"date":186,"type":21},"2028-05-25",{"name":46,"class":47},{"id":189,"slug":190,"hasResults":11,"nctId":191,"briefTitle":192,"officialTitle":193,"acronym":194,"eligibilityCriteria":195,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":196,"targetDuration":4,"studyType":22,"phases":198,"briefSummary":199,"conditions":200,"keywords":201,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":204,"lastUpdatePostDateStruct":205,"startDateStruct":207,"completionDateStruct":209,"leadSponsor":211,"locationsCount":212},"100409668","phase-2-exome-analysis-complexe-vs-simple-to-help-the-therapeutic-decision-for-the-precision-medicine-100409668","NCT04614480","Exome Analysis (Complexe vs Simple) to Help the Therapeutic Decision for the Precision Medicine","A Multicenter, Prospective, Multi-organ Study to Evaluate the Clinical Benefit of an Exome \"Complex\" Analysis Versus an Exome \"Simple\" Analysis to Help the Therapeutic Decision for the Precision Medicine","EXOMA2","Inclusion Criteria:\n\n1. Age ≥ 18 years old\n2. Weight\\> 30 Kg\n3. Histological or cytological evidence of the diagnosis of a metastatic or locally advanced solid tumor\n4. Patient in 1st line of treatment for metastatic or locally advanced disease\n5. Tumor material available in sufficient and usable quantity for the analyzes required by the study\n6. Request for exome analysis to be carried out when initiating the 1st or 2nd line of treatment (line initiated at the time of inclusion)\n7. Life expectancy estimated to be probably ≥ 6 months.\n8. WHO ≤ 1\n9. Patient capable and willing to follow all study procedures in accordance with the protocol\n10. Patient having understood the purpose, risks and constraints of the study and having signed and dated the consent form\n11. Patient affiliated to the social security scheme.\n\nExclusion Criteria:\n\n1. Tumor material not available or biopsy not possible.\n2. Inability to take a blood test.\n3. Refusal of genetic analysis.\n4. Patient likely to progress within 3 months of inclusion in the study.\n5. History of HIV \u002F HBV \u002F HCV infection.\n6. Patient already included in the EXOMA or EXOMA2 study.\n7. Woman who is pregnant, may be, or is breastfeeding.\n8. Persons deprived of their liberty or under guardianship (including curatorship).",{"count":197,"type":21},7976,[174],"The \"simple\" analysis of the exome can determine somatic and constitutional mutations. The major challenge lies in the translation of sequencing data into clinically relevant information allowing the clinician to guide his decision-making A \"complex\" analysis of the exome would provide access to structural DNA data, concerning mutational signatures, tumor mutational load, analysis of large deletions, loss of heterozygosity as well as amplification of certain genes which may have an impact on the management of patients.\n\nNo data available to date makes it possible to assess the clinical interest of the availability of its additional information resulting from a \"complex\" analysis compared to a \"simple\" analysis. The objective of the EXOMA2 study is to assess the proportion of patients for whom the proposed therapy is derived from its additional information (complex analysis) and would not have been possible with a classic exome analysis (simple analysis) .\n\nWe hereby formulate the hypothesis that a \"complex\" analysis on a population presenting a metastatic or locally advanced disease treated early (from the 1st line of treatment) will make it possible to determine therapeutic indications which could not be discovered with a \"simple\" analysis.",[88],[202,203],"genetic","exome","2025-09-16",{"date":206,"type":40},"2025-09-22",{"date":208,"type":40},"2020-08-25",{"date":210,"type":21},"2032-09-02",{"name":46,"class":47},12,{"id":214,"slug":215,"hasResults":11,"nctId":216,"briefTitle":217,"officialTitle":218,"acronym":219,"eligibilityCriteria":220,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":221,"targetDuration":4,"studyType":22,"phases":223,"briefSummary":224,"conditions":225,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":234,"completionDateStruct":236,"leadSponsor":238,"locationsCount":4},"100600138","emergence-of-bacterial-resistance-to-antibiotics-in-the-digestive-microbiota-of-patients-treated-with-anticancer-drugs-100600138","NCT07093593","Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticancer Drugs","Emergence of Bacterial Resistance to Antibiotics in the Digestive Microbiota of Patients Treated With Anticancer Drugs (Clinical Component of the RAMA Project)","RAMA","Inclusion Criteria:\n\n* Men and women over 18\n* Chemotherapy-naive patients.\n* Patients due to start chemotherapy\u002Fradio chemotherapy who meet the criteria of the cohorts listed below :\n\n  1. Squamous cell carcinoma of the upper aerodigestive tract (Non-metastatic, locally advanced, operable or not; Patients receiving concomitant radiochemotherapy using a platinum salt (cisplatin, carboplatin))\n  2. Cervical and endometrial cancer (ocally advanced, Non-metastatic; Patients receiving concomitant radiochemotherapy using a platinum salt (cisplatin, carboplatin))\n  3. Gynecological cancer (advanced stage ; Patient to receive platinum salt + paclitaxel chemotherapy)\n  4. Mammary carcinoma (localised; Patient to receive adjuvant or neoadjuvant chemotherapy with epirubicin and cyclophosphamide without other associated treatment (targeted therapy \u002F immunotherapy))\n  5. Urothelial carcinoma (all stage ; Patient to receive neoadjuvant or adjuvant chemotherapy with platinum salt and gemcitabine)\n  6. Pancreatic adenocarcinoma (localised or metastatic ; Patients to be treated with gemcitamine alone or in combination with nab-paclitaxel)\n* OMS ≤ 2\n* Affiliation with a French social security scheme or beneficiary of such a scheme.\n* Signed informed consent indicating that the patient has understood the purpose and procedures of the study and agrees to participate in the study and to abide by the study requirements and restrictions\n\nExclusion Criteria:\n\n* Patients unable to collect \u002F send stools for medical, geographical, social or psychological reasons.\n* Patients who have already received chemotherapy\u002Fradiochemotherapy.\n* Use of anti-infectives for systemic use within 6 months prior to the first sampling, or any other concomitant disease\u002Fcondition that may influence stool analysis.\n* Pregnant women and nursing mothers.\n* Persons deprived of their liberty by judicial or administrative decision; persons under compulsory psychiatric care; persons admitted to a health or social institution for purposes other than research.\n* Adults subject to a legal protection measure - safeguard of justice, guardianship or curatorship - or unable to express their consent.",{"count":222,"type":21},260,[59],"Solid cancers are frequently treated with chemotherapies that target the DNA of cancer cells. It has recently come to light that bacteria are also the target of chemotherapies used in oncology. The results of current studies demonstrate the close link between the composition of the microbiota, the immune system, toxicity and the efficacy or otherwise of anti-cancer treatments.\n\nIn this context, the study will measure the influence of treatment with anticancer molecules known to activate the bacterial SOS response on the emergence of antibiotic-resistant commensal bacteria in the gut microbiota of cancer patients. Furthermore, this study will investigate the existence of a close link between changes in the intestinal microbiota determined by the induction or non-induction of the SOS response, bacterial translocation, the integrity of the intestinal barrier and the antitumor immune response.\n\nThe RAMA trial plans to collect stool and blood samples from two different cohorts of patients:\n\n* Unexposed cohort: patients receiving anti-cancer treatment that does not induce bacterial SOS response.\n* Exposed cohort: patients receiving anti-cancer treatment inducing the bacterial SOS response.\n\nPatients' stools will be collected within 7 days of their first chemotherapy treatment and within 7 days of the 3rd chemotherapy cycle. Two blood samples will be taken at the same time as the stool samples.\n\nThe results obtained from this prospective clinical research will then be investigated in two experimental laboratory models.\n\nThe aim is to demonstrate that cytotoxic anticancer drugs promote the emergence of antibiotic-resistant commensal bacteria, by means of this large-scale study comprising a clinical component, which is the subject of the research presented in this protocol, combined with laboratory research components.",[226,227,228,229,230],"Cervical Cancers","Endometrial Cancer","Gynecological Cancers","Pancreatic Adenocarcinoma","Upper Aerodigestive Tract Carcinoma","2025-07-22",{"date":233,"type":40},"2025-07-30",{"date":235,"type":21},"2025-09-01",{"date":237,"type":21},"2032-09-01",{"name":46,"class":47},{"id":240,"slug":241,"hasResults":11,"nctId":242,"briefTitle":243,"officialTitle":243,"acronym":244,"eligibilityCriteria":245,"healthyVolunteers":246,"sex":17,"minAge":18,"maxAge":247,"enrollmentInfo":248,"targetDuration":4,"studyType":22,"phases":250,"briefSummary":251,"conditions":252,"keywords":254,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":260,"lastUpdatePostDateStruct":261,"startDateStruct":263,"completionDateStruct":265,"leadSponsor":267,"locationsCount":48},"100588680","phase-2-evaluation-of-the-effect-of-adapted-physical-activity-on-the-modification-of-lipid-metabolism-during-chemotherapy-for-metastatic-colorectal-cancer-100588680","NCT06944548","Evaluation of the Effect of Adapted Physical Activity on the Modification of Lipid Metabolism During Chemotherapy for Metastatic COLorectal Cancer","APACOL","Inclusion Criteria for patients:\n\n* Age ≥ 18 years\n* Patient with histologically proven metastatic colorectal cancer\n* Patient eligible for treatment with chemotherapy, in combination or not with other anti-cancer treatments according to standard management\n* Have a performance status of 0 or 1 according to the WHO ECOG index\n* Blood albumin value ≥30g\u002FL\n* Patient able to give consent and able to undergo study monitoring, including visits, physical activities, blood sampling\n* Patient affiliated to a social security scheme or equivalent.\n\nInclusion Criteria for healthy volunteers :\n\n* Age ≥ 18 years ≤ 80 years\n* Persons capable of giving signed informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form and in this protocol. Written informed consent and any required authorisation must be obtained from the healthy volunteer prior to carrying out any procedure related to the protocol, including examinations to assess the eligibility of the person\n* Persons who are affiliated to or are beneficiaries of a social security scheme according to local requirements.\n\nExclusion Criteria for patients :\n\n\\- Independent physical activity exceeding INCa recommendations: Moderate physical activity greater than or equal to 300 minutes\u002Fweek (≥5h) or intense physical activity greater than or equal to 150 minutes\u002Fweek (≥2.5h)).\n\n* Specific diet and\u002For any lipid-lowering treatment within 15 days prior to randomisation.\n* Metformin treatment within 15 days prior to randomisation.\n* Any medical conditions or co-morbidities likely to contraindicate the practice of physical activity. The list below is not exhaustive:\n\nPrevious stroke Myocardial infarction in the 6 months prior to inclusion Uncontrolled arterial hypertension Severe cardiovascular or respiratory disease Rheumatological\u002Forthopaedic conditions or bone lesions at risk of fracture\n\n* Presence of symptomatic cerebral metastasis(es).\n* Prognosis estimated at less than 3 months.\n* Unable to undergo medical monitoring of the trial and the various visits for geographical, social or psychological reasons.\n* Persons deprived of their liberty or under guardianship (including curatorship).\n* Pregnant or breast-feeding women (pregnancy test compulsory at inclusion).\n* The patient does not have internet access \u002F a smartphone \u002F does not wish to download the AXOMOVE application required to take part in the study.\n\nExclusion Criteria for healthy volunteers :\n\n* Patients with a history of cancer other than basal cell cancer, or who have already received systemic anti-cancer treatment.\n* Persons with a special diet, metformin treatment and\u002For any lipid-lowering treatment in the 15 days prior to inclusion.\n* Persons with moderate physical activity exceeding 300 minutes\u002Fweek or intense physical activity exceeding 150 minutes\u002Fweek.\n* Persons deprived of their liberty or under guardianship (including curatorship).\n* Pregnant or breast-feeding women (pregnancy test compulsory at inclusion).",true,"80 Years",{"count":249,"type":21},54,[174],"APACOL is a pilot, bicentric, randomised, open-label, prospective, category 2 study. The presence of colon cancer modifies blood lipid parameters which are likely to have an impact on the efficacy of anti-cancer treatments. Previous data support the hypothesis that appropriate physical activity could modify the blood lipid parameters involved in chemoresistance in patients with metastatic colorectal cancer.\n\nThe aim of the APACOL study is to investigate the impact of modulating the frequency (volume per week) of physical activity recommended by INCa on the variation in lipid parameters involved in chemoresistance in patients with metastatic colon cancer, with a reference level of these lipid parameters in people without cancer provided by the participation of volunteers who are not ill.\n\nThe expectations at the end of this study are an improvement in the patient's quality of life \u002F an improvement in the tolerance and efficacy of the chemotherapy treatment \u002F identification of the frequency of APAs needed to vary the lipid metabolism involved in chemoresistance.",[27,253],"Volunteer Subjects",[255,256,257,258,259],"No special diet","ECOG 0 or 1","Blood albumin ≥30g\u002FL","Age ≥ 18 years","Patients eligible for chemotherapy treatment","2025-04-25",{"date":262,"type":40},"2025-04-30",{"date":264,"type":21},"2025-06-01",{"date":266,"type":21},"2030-06-01",{"name":46,"class":47},{"id":269,"slug":270,"hasResults":11,"nctId":271,"briefTitle":272,"officialTitle":272,"acronym":273,"eligibilityCriteria":274,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":275,"targetDuration":4,"studyType":147,"phases":4,"briefSummary":277,"conditions":278,"keywords":280,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":283,"lastUpdatePostDateStruct":284,"startDateStruct":286,"completionDateStruct":288,"leadSponsor":290,"locationsCount":48},"100524644","use-of-an-ultra-rapid-brca12-status-screening-test-in-diagnostic-and-theranostic-indication-performance-and-interest-for-patients-and-practitioners-100524644","NCT06111417","Use of an Ultra-rapid BRCA1\u002F2 Status Screening Test in Diagnostic and Theranostic Indication: Performance and Interest for Patients and Practitioners","TURBO","Inclusion Criteria:\n\n* Age ≥ 18 years\n* Indication for oncogenetic consultation with a wide panel test including BRCA1\u002F2 (gold standard) as part of the standard theranostic and diagnostic management of breast cancer.\n* The patient agrees to take part in the study, to follow all the study procedures and to complete the questionnaires sent during the consultation or by email.\n* Diagnosis of the disease ≤ 6 months\n* The patient must be affiliated to the social security system.\n\nExclusion Criteria:\n\n* Concomitant disorder or condition likely to compromise understanding of study information or completion of questionnaires\n* Patients who do not have an email address and\u002For do not have internet access or tools to connect to the internet\n* Women who are pregnant, may become pregnant or are breast-feeding\n* Persons deprived of their liberty or under guardianship (including curatorship)\n* Inability to undergo trial monitoring for geographical, social or psychological reasons.",{"count":276,"type":21},150,"The time taken to obtain the results of germline mutations in BRCA1 and BRCA2 has become a major issue in adapting the therapeutic management of patients, particularly those with breast cancer.\n\nThe time taken to obtain the results of BRCA1\u002F2 tests in routine laboratories with a view to personalised treatment can range from a few weeks to a few months. The waiting time required to obtain results is likely to cause stress and anxiety in cancer patients. The investigators hypothesise that ultra-rapid testing can reduce anxiety about patients' genetic status and improve their mental well-being.\n\nThe main objective of this project is to compare the results obtained with an ultra-fast kit developed by O.N.T with those obtained with the current gold standard, NGS sequencing.",[279],"Breast Cancer",[281,282],"BRCA 1\u002F2","breast cancer","2025-04-17",{"date":285,"type":40},"2025-04-22",{"date":287,"type":40},"2024-06-12",{"date":289,"type":21},"2026-09-12",{"name":46,"class":47},{"id":292,"slug":293,"hasResults":11,"nctId":294,"briefTitle":295,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":299,"targetDuration":4,"studyType":22,"phases":301,"briefSummary":302,"conditions":303,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":309,"startDateStruct":311,"completionDateStruct":313,"leadSponsor":314,"locationsCount":48},"100558405","study-of-cancer-patients-preferences-for-genetic-information-modalities-preceding-theranostic-exome-analysis-100558405","NCT06550687","Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis.","Study of Cancer Patients' Preferences for Genetic Information Modalities Preceding Theranostic Exome Analysis. Qualitative Observational and Interventional Cross-sectional Study","INFOGENE","Inclusion Criteria:\n\n* Patient identified for inclusion in the EXOMA 2 study (exome analysis request)\n* Available to receive different types of information\n* Fluent in French\n* No prior oncogenetic consultation\n* Having been informed of the objectives of the study and having given written non-objection to participate in the INFOGene study\n* Authorizing audio recording of consultations and interviews\n\nExclusion Criteria:\n\n* Patient who refused to participate in the EXOMA2 study (for phase 3 patients only)\n* Has a psychiatric, cognitive or neurological disorder that makes participation impossible\n* Working in the field of genetics",{"count":300,"type":21},80,[59],"Currently, the EXOMA2 study (NCT04614480) offers earlier and more comprehensive exome analysis in the management of cancer patients than EXOMA. Based on the active EXOMA2 patient file, the INFOGene study offers the opportunity to study patient-physician communication, to assess patient preferences with regard to different information modalities concerning theranostic exome analysis, and to reflect on information modalities to ensure optimal patient comprehension of the information provided.\n\nThe qualitative cross-sectional study includes a dual observational and interventional component involving cancer patients. The patients will come from the EXOMA 2 active file at Dijon University Hospital and the CGFL.",[304,305,306,307],"All Types of Metastatic Solid Malignancy","1st-line Treatment","Exome Analysis","Active File EXOMA2 Study","2025-02-14",{"date":310,"type":40},"2025-02-18",{"date":312,"type":40},"2024-09-19",{"date":42,"type":21},{"name":46,"class":47},{"id":316,"slug":317,"hasResults":11,"nctId":318,"briefTitle":319,"officialTitle":319,"acronym":320,"eligibilityCriteria":321,"healthyVolunteers":11,"sex":17,"minAge":322,"maxAge":4,"enrollmentInfo":323,"targetDuration":4,"studyType":22,"phases":325,"briefSummary":326,"conditions":327,"keywords":330,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":338,"startDateStruct":340,"completionDateStruct":342,"leadSponsor":344,"locationsCount":137},"100499488","impact-of-non-magnetic-screen-respiratory-self-guidance-during-mri-guided-radiotherapy-sessions-for-mobile-lesions-100499488","NCT05783908","Impact of Non-magnetic Screen Respiratory Self-guidance During MRI-guided Radiotherapy Sessions for Mobile Lesions","RespEcran","Inclusion Criteria:\n\n* Patient is at least 18 years old\n* Patient starting radiotherapy on Linac MRI for a mobile cancerous lesion most often in the pancreas, liver, kidneys, adrenals, lung, supra or subdiaphragmatic adenopathy\n* Patient affiliated to the social security system\n\nExclusion Criteria:\n\n* Patient with lesions not detected by the device's tracking system\n* Patient with visual disturbances\n* Contraindications to treatment with Linac MRI (epileptic patients, pregnant or breastfeeding women, metallic prosthesis or pacemaker not compatible with MRI)\n* Patients with cognitive disorders\n* Persons deprived of liberty or under guardianship (including curatorship)\n* Pregnant or nursing woman\n* Refusal to participate in the study","18 Months",{"count":324,"type":21},100,[59],"The patients eligible for the study are those treated by radiotherapy on Linac MRI for a mobile cancerous lesion (pancreas, liver, kidneys, adrenals, lung, adenopathy above or below the diaphragm ...).\n\nAfter signing the consent form, each patient will be randomized to one of two treatment arms:\n\n* Standard arm : Radiotherapy treatment with Linac MRI without non-magnetic shielding\n* Experimental arm : radiotherapy treatment with Linac MRI with non-magnetic screen The aim is to evaluate the effect of using a non-magnetic screen visible to the patient in the bunker during radiotherapy sessions delivered by Linac MRI on decreasing the ratio between the actual treatment time and the treatment time predicted by the machine.",[328,329],"Patient With Radiotherapy (Linac MRI)","Mobile Cancerous Lesion",[331,332,333,334,335,336,337],"Linac IRM","Pancreatic cancer","Liver cancer","Kidney cancer","Adrenal cancer","Lung cancer","Adenopathy above or below the diaphragm",{"date":339,"type":40},"2025-02-17",{"date":341,"type":40},"2023-10-16",{"date":343,"type":21},"2025-09-27",{"name":46,"class":47},{"id":346,"slug":347,"hasResults":11,"nctId":348,"briefTitle":349,"officialTitle":350,"acronym":351,"eligibilityCriteria":352,"healthyVolunteers":11,"sex":353,"minAge":18,"maxAge":354,"enrollmentInfo":355,"targetDuration":4,"studyType":22,"phases":357,"briefSummary":358,"conditions":359,"keywords":4,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":308,"lastUpdatePostDateStruct":361,"startDateStruct":362,"completionDateStruct":364,"leadSponsor":366,"locationsCount":48},"100317798","study-evaluating-the-efficacy-and-the-tolerance-of-pelvic-prostatic-hypo-fractionated-radiotherapy-followed-by-boost-in-patients-with-prostate-adenocarcinoma-adverse-intermediate-risk-or-high-localized-risk-100317798","NCT03417336","Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk","Multicenter, Randomized, Pilot Study Evaluating the Efficacy and the Tolerance of Pelvic-prostatic Hypo-fractionated Radiotherapy Followed by Boost (Stereotaxic External Radiotherapy or High Dose Rate Brachytherapy) in Patients With Prostate Adenocarcinoma Adverse Intermediate Risk or High Localized Risk","SHORT","Inclusion Criteria:\n\n1. Adenocarcinoma of the prostate\n2. Patient with one of the following cases:\n\n   * Gleason 7 - 10 + T1c - T2b + PSA \\\u003C 50 ng\u002FmL or\n   * Gleason 6 + T2c - T4 ou envahissement ≥ 50% sur les biopsies + PSA \\\u003C 50 ng\u002FmL or\n   * Gleason 6 + T1c - T2b + PSA \\> 20 ng\u002FmL\n3. Risk of lymph node involvement\\> 15%\n4. Patient N0, or Nx\n5. Prostate volume estimated on MRI or ultrasound less than 60 cc.\n6. Absence of pelvic lymphadenopathy ≥ 15 mm on CT or MRI extension assessment\n7. Lack of bone and \u002F or visceral metastasis on CT scan and bone scintigraphy\n8. Hormonal treatment started maximum 90 days before the beginning of the irradiation,\n9. IPSS score \\\u003C12 without alpha blocker treatment\n10. Absence of prior pelvic radiotherapy,\n11. Lack of surgical treatment for prostate cancer except transurethral resection performed within 6 months before radiotherapy,\n12. Age ≥ 18 years and ≤ 85 years,\n13. WHO performance index ≤ 1,\n14. Estimated life expectancy\\> 5 years,\n15. Indication of treatment with radiotherapy and validated hormone therapy in a multidisciplinary consultation meeting\n16. Affiliation to a social security scheme,\n17. Signed informed consent.\n\nExclusion Criteria:\n\n1. Prostate cancer of histology other than adenocarcinoma,\n2. Patient diagnosed with N1 during imaging or pN1,\n3. serum PSA level\\> 100 ng \u002F ml,\n4. IPSS score ≥ 12 or alpha blocker treatment,\n5. Prostate volume estimated on MRI or ultrasound\\> 60 cc\n6. History of cancer in the 5 years prior to entry into the trial,\n7. History of trans-urethral resection of prostate less than 6 months old,\n8. History of rectal surgery,\n9. History of pelvic irradiation,\n10. Patient with severe hypertension not controlled by appropriate treatment,\n11. Contraindication to pelvic irradiation,\n12. Patient not eligible for brachytherapy\n\n    * Prostate volume\\> 60cc\n    * Urine flow measurement with max flow \\\u003C12 mL \u002F s\n    * Or curative anticoagulant treatment\n    * Or contraindication to general anesthesia\n13. Patient treated with antineoplastic or drug may include methotrexate,\n14. Hormone therapy started\\> 90 days before the first irradiation,\n15. Patient on immunosuppressant therapy\n16. Contraindication to agonists or antagonists of LHRH,\n17. Bilateral hip prosthesis,\n18. Patient already included in another therapeutic trial with an experimental molecule,\n19. Patient unable to cooperate during treatment,\n20. Persons deprived of their liberty or guardianship,\n21. Inability to undergo medical follow-up of the test.","MALE","85 Years",{"count":356,"type":21},90,[59],"The standard treatment of high-risk prostatic adenocarcinoma is based on pelvic-prostatic external radiotherapy combined with concomitant and adjunctive hormone therapy for a total of 3 years.\n\nProstatic stereotactic radiotherapy in 5 sessions is a therapeutic option currently delivered and described in multiple cohorts of patients with a tolerance comparable to normo-fractional treatments. This therapeutic scheme makes it possible to deliver a higher equivalent biological dose than during a treatment carried out with a conventional fractionation.\n\nThe results with a follow-up of 9 years are extremely encouraging and do not show any excess toxicity compared to other irradiation techniques. They confirm that urinary and digestive toxicities are acceptable. All these studies did not involve pelvic irradiation. Several trials have also demonstrated the feasibility of normofractionated pelvic irradiation associated with hypofractionated prostatic irradiation using an integrated boost technique.\n\nThe primary objective is to evaluate, for localized high-risk prostate cancers (unfavorable intermediate or high risk), the rate of digestive and urinary toxicity cumulated at 3 months of the association of a pelvi-prostatic irradiation contracted in 5 sessions, with:To evaluate, for localized high-risk prostate cancers (unfavorable intermediate or high risk), the rate of digestive and urinary toxicity cumulated at 3 months of the association of a pelvi-prostatic irradiation contracted in 5 sessions, with:\n\n* a prostatic boost in brachytherapy with high dose rate (HDR) or\n* an integrated boost in stereotaxis (in case of contraindication to brachytherapy)",[360],"To Evaluate the Rate of Digestive and Urinary Toxicity",{"date":339,"type":40},{"date":363,"type":40},"2018-01-24",{"date":365,"type":21},"2029-04-24",{"name":46,"class":47},{"id":368,"slug":369,"hasResults":11,"nctId":370,"briefTitle":371,"officialTitle":372,"acronym":373,"eligibilityCriteria":374,"healthyVolunteers":11,"sex":375,"minAge":322,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":22,"phases":378,"briefSummary":379,"conditions":380,"keywords":381,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":137},"100492681","phase-2-randomized-study-versus-placebo-for-the-prevention-of-neurotoxicity-induced-by-weekly-paclitaxel-100492681","NCT05695313","Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL","Phase II Multicentric, Randomized Study Versus Placebo for the Prevention of Neurotoxicity Induced by Weekly PACLITAXEL","NEUROTAX","Inclusion Criteria:\n\n* Breast cancer patient with neo-adjuvant or adjuvant management, with an indication for weekly PACLITAXEL 80 mg\u002Fm² for 12 courses.\n* Age ≥ 18 years\n* Performans Status ≤ 3 according to Karnofsky and life expectancy greater than 6 months\n* For patients of childbearing age, effective contraception while taking Onlife®\u002Fplacebo.\n* Patient able to swallow OnLife\u002Fplacebo® tablets easily\n* Patient able and willing to follow all study procedures (including the completion of numerous questionnaires) in accordance with the protocol\n* Patient has understood, signed and dated the consent form\n* Patient affiliated to the social security system\n\nExclusion Criteria:\n\n* Patient previously started on PACLITAXEL\n* Known allergy to any of the substances in the study product Onlife®\u002Fplacebo (fish oil product)\n* Diabetes\n* Exogenous (Alcoholism)\n* History of peripheral neuropathy at inclusion and\u002For presence of sensory and\u002For motor disorders due to other neurological diseases\n* Pregnant or breastfeeding woman\n* Other uncontrolled progressive pathologies\n* Impossible or random follow-up\n* Persons deprived of liberty or under guardianship (including curatorship)\n* Inability to submit to the medical follow-up of the trial for geographical, social or psychological reasons.","FEMALE",{"count":377,"type":21},60,[174],"This study recommends the use of OnLife dietary supplement, which will be followed by a few day before the initiation of PACLITAXEL, for the prevention of PACLITAXEL induced neuropathy. OnLife will be continued one month after stopping chemotherapy.\n\nThis would limit the number of PACLITAXEL dose reductions and premature interruptions of this chemotherapy, thus potentially improving the results in terms of antitumor efficacy, while improving the quality of life of patients treated with weekly PACLITAXEL.",[279],[382,383,384,385,386],"breast","neuropathy","OnLife","dietary supplement","Paclitaxel","2024-04-19",{"date":389,"type":40},"2024-04-22",{"date":391,"type":40},"2024-04-12",{"date":393,"type":21},"2026-06-30",{"name":46,"class":47},{"id":396,"slug":397,"hasResults":11,"nctId":398,"briefTitle":399,"officialTitle":400,"acronym":401,"eligibilityCriteria":402,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":403,"targetDuration":4,"studyType":22,"phases":404,"briefSummary":405,"conditions":406,"keywords":407,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":411,"lastUpdatePostDateStruct":412,"startDateStruct":414,"completionDateStruct":416,"leadSponsor":418,"locationsCount":137},"100515231","phase-2-trial-evaluating-the-efficacy-and-the-safety-of-folfirinox3-treatment-in-patients-with-unresectable-locally-advanced-or-metastatic-pancreatic-cancer-in-first-line-of-chemotherapy-100515231","NCT05988814","Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy","Phase II Trial Evaluating the Efficacy and the Safety of FOLFIRINOX3 Treatment in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer in First Line of Chemotherapy (FOLFIRINOX3 Pancréas)","FOLFIRINOX3 P","Inclusion Criteria:\n\n* Male or female age \\> 18 years at time of study entry\n* Performance status of 0 or 1 according to the Eastern Cooperative Oncology Group (ECOG)\n* Patients with pancreatic adenocarcinoma\n* Patients with unresectable locally advanced pancreatic cancer or metastatic pancreatic cancer\n* Patients with no history of chemotherapy (prior adjuvant or neoadjuvant chemotherapy accepted if the time between the end of chemotherapy and recurrence is greater than 12 months) and no history of curative radiotherapy for metastatic or locally advanced disease. Palliative radiotherapy is accepted.\n* Patient eligible for treatment with FOLFIRINOX (5-FU, Irinotecan, Oxaliplatin and folinic acid) including but not limited to: No active heart disease An ECG with a QT\u002FQTc interval ˂ to 450 ms for men and ˂ to 470 ms for women. No uncontrolled hypertension defined by systolic pressure \\> 140 mmHg or diastolic pressure \\> 90 mmHg despite optimal medical management. A negative pregnancy test if applicable\n* Tumor evaluation (CT scan) performed within 4 weeks (28 days) prior to inclusion with at least one measurable lesion according to RECIST 1.1 criteria\n* Patient fit and able to comply with the protocol for the duration of the study, including treatment, visits, scheduled examinations and follow-up.\n* Biological, hepatic, renal and serological data within the following limits (tests performed within 7 days of inclusion except for serologies performed within 28 days)\n* Information given and informed consent signed\n* Patient affiliated to a social security scheme\n* Men and women must have an effective contraceptive method.\n\nExclusion Criteria:\n\n* Patient with neuroendocrine carcinoma or acinar cell carcinoma\n* Other cancer in the 5 years preceding inclusion or concomitant (except cancer in situ of the uterine cervix or cutaneous basal cell carcinoma).\n* Presence of brain metastasis(es)\n* Estimated prognosis \\\u003C 3 months\n* History of grade 4 toxicity to oxaliplatin, irinotecan or 5FU if history of adjuvant\u002Fneoadjuvant chemotherapy\n* Sequellar toxicity \\> grade 1 if previous adjuvant\u002Fneoadjuvant chemotherapy\n* Hypersensitivity to any component of FOLFIRINOX® treatment.\n* Current participation or participation within 30 days prior to inclusion in another therapeutic trial with an investigational compound and\u002For completion of radiotherapy within 10 days prior to the start of treatment\n* Evidence of a homozygous or heterozygous DPYD mutation and\u002For uracilemia \\>16ng\u002FmL and\u002For homozygous UGT1A1 genotype.\n* Pregnancy, breastfeeding\n* Inability to sign informed consent or to undergo medical monitoring of the trial for geographical, social or psychological reasons including, but not limited to, psychiatric illness compromising comprehension of information or conduct of the study.\n* Patient under guardianship, curatorship or safeguard of justice.",{"count":356,"type":21},[174],"Evaluate the efficacy of treatment FOLFORINOX 3 in first-line therapy for patients with locally advanced unresectable or metastatic pancreatic cancer.",[29],[408,409,410],"FOLFIRINOX treatment","pancreatic cancer","first line chemotherapy","2024-02-09",{"date":413,"type":40},"2024-02-12",{"date":415,"type":40},"2024-01-24",{"date":417,"type":21},"2029-07-24",{"name":46,"class":47},{"id":420,"slug":421,"hasResults":11,"nctId":422,"briefTitle":423,"officialTitle":423,"acronym":424,"eligibilityCriteria":425,"healthyVolunteers":11,"sex":353,"minAge":18,"maxAge":4,"enrollmentInfo":426,"targetDuration":4,"studyType":22,"phases":428,"briefSummary":429,"conditions":430,"keywords":432,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":437,"lastUpdatePostDateStruct":438,"startDateStruct":440,"completionDateStruct":442,"leadSponsor":444,"locationsCount":4},"100526564","evaluation-of-the-concordance-between-pre-therapy-dosimetry-performed-from-68ga-psma-11-dynamic-pet-and-post-treatment-dosimetry-of-177lu-psma-617-vectorized-internal-radiotherapy-in-patients-with-metastatic-prostate-cancer-resistant-to-hormonal-castration-100526564","NCT06136377","Evaluation of the Concordance Between Pre-therapy Dosimetry Performed From 68Ga-PSMA-11 Dynamic PET and Post-treatment Dosimetry of 177Lu-PSMA-617 Vectorized Internal Radiotherapy in Patients With Metastatic Prostate Cancer Resistant to Hormonal Castration.","GaLuPro","Inclusion Criteria:\n\n* Patients over 18 with histologically proven metastatic prostate cancer treated with taxane chemotherapy plus at least one second-generation hormone therapy and resistant to hormonal castration (eligibility criterion for 177Lu-PSMA IVR treatment).\n* Patient referred to CGFL for standard disease management with indication for 18F-FDG PET, 18F-Choline PET and 68Ga-PSMA-11 PET to validate patient's eligibility for 177Lu-PSMA-617 IVR treatment.\n* ECOG ≤ 2\n* Life expectancy ≥ 6 months\n* No unacceptable medical or radiological risk for isolation in a nuclear medicine therapy unit.\n* Patient informed about the study, able to understand the study constraints and sign the consent form.\n* Patient affiliated to the social security system or equivalent\n\nExclusion Criteria:\n\n* Inability of the patient to maintain a lying position, without moving, for more than 1 hour (1 hour 20 minutes of acquisition for the dynamic PET acquisition specific to the GaLuPro study).\n* Allergy to 68Ga-PSMA-11 or 177Lu-PSMA-617\n* Contraindications to receiving 177Lu-PSMA IVR treatment and\u002For performing the imaging tests required by the protocol (patient with pacemaker or defibrillator).\n* Urinary tract obstruction or hydronephrosis. Patients with a diagnosis or high risk of urinary retention and\u002For fitted with a urinary catheter and\u002For with incontinence making urine collection impossible or PET examinations impossible.\n* Patient refusal to participate in study\n* Impossibility for the patient to undergo medical monitoring and compliance with treatment and trial procedures for geographical, social or psychological reasons.\n* Persons deprived of their liberty or under guardianship (including curatorship)",{"count":427,"type":21},35,[59],"Patients undergo three diagnostic PET scans: 18F-FDG PET scan \u002F 18F-Choline PET scan and 68Ga-PSMA PET scan. Following the diagnostic PET scans, and if patients' eligibility for 177Lu-PSMA-617 IVR treatment is confirmed, SPECT acquisitions will be performed during the first treatment course at 5h, 24h, 4 days and 8 days for dosimetric control.\n\nThe patient will then return to the nuclear medicine department to undergo SPECT\u002FCT (3 FOV) acquisitions using the same methods as those presented above and recommended in the standard management at : D+24h post-injection, D+4d post-injection and D+8d post-injection No further research-specific acts or procedures will be performed at the end of the first treatment course.\n\nContinuity of treatment will be carried out in accordance with standard management and treatment requirements and modalities, as will clinical, biological and radiological follow-up.",[431],"Patients With Metastatic Castration-resistant Prostate Cancer",[433,434,435,436],"nuclear medicine","prostate cancer","taxane chemotherapy","68Ga-PSMA-11","2023-11-13",{"date":439,"type":40},"2023-11-18",{"date":441,"type":21},"2024-01-31",{"date":443,"type":21},"2027-01-31",{"name":46,"class":47},{"id":446,"slug":447,"hasResults":11,"nctId":448,"briefTitle":449,"officialTitle":449,"acronym":450,"eligibilityCriteria":451,"healthyVolunteers":11,"sex":375,"minAge":18,"maxAge":354,"enrollmentInfo":452,"targetDuration":4,"studyType":22,"phases":453,"briefSummary":454,"conditions":455,"keywords":456,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":459,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":465,"locationsCount":48},"100433571","immunomonitoring-of-breast-cancer-patients-during-systemic-treatment-100433571","NCT04925856","Immunomonitoring of Breast Cancer Patients During Systemic Treatment","IMMUNE CAPTURE","Inclusion Criteria:\n\n1. Woman aged between 18 and 85.\n2. Patient with histologically proven infiltrating breast cancer.\n3. Triple negative breast cancer or RH + \u002F HER2- (OR and RP \\\u003C10% and HER2 negative (0 or 1+ in IHC or 2+ in IHC and FISH negative)\n4. Patient receiving treatment corresponding to one of these cohorts:\n\n   * In a metastatic situation with establishment of treatment with Paclitaxel regardless of the treatment line\n   * In a metastatic situation with establishment of treatment with Epirubicin - cyclophosphamide (EC) regardless of the treatment line\n   * In a metastatic situation with establishment of treatment with Eribulin regardless of the line of treatment\n   * In a 1st line metastatic situation with initiation of treatment with Palbociclib or Abemaciclib, or Ribociclib in combination with hormone therapy (aromatase inhibitor)\n5. Patient who signed the informed consent for the study.\n6. Patient fit and able to adhere to protocol for the duration of the study, including visits, scheduled specimens and follow-up.\n7. Patient affiliated to the social security system.\n\nExclusion Criteria:\n\n1. Patient unable to understand, read and \u002F or sign informed consent.\n2. Presence of cerebral or meningeal metastasis\n3. Current or previous use of an immunosuppressive drug in the 14 days preceding inclusion (except intranasal corticosteroids, systemic corticosteroids at physiological doses not exceeding 10 mg per day of prednisone or its equivalent, corticosteroids for antiemetic purposes, corticosteroids used as premedication for hypersensitivity reactions (injected CT scan, taxanes, etc.)\n4. Patient participating in another research that may modify the systemic treatment administered in the framework of the cohort in which she will be included.\n5. Pregnant or breastfeeding woman.\n6. HIV and \u002F or HBV and \u002F or HCV serology positive.\n7. Life expectancy estimated at less than 3 months.\n8. Patient's refusal.\n9. Person benefiting from a protection system for adults (including tutorship and curatorship).\n10. Inability to undergo medical monitoring of the trial for geographical, social or psychological reasons.",{"count":276,"type":21},[59],"This study aims to constitute a most complete biological collection for patients treated for localized or metastatic breast cancer (in different cohorts depending on the type of systemic treatment received), in order to describe the basal immune response of patients treated for a breast cancer according to the stage of the disease, but above all to study how the different systemic treatments used in the management of breast cancer modulate this immune response.",[279],[457,458],"immune response","blood samples",{"date":460,"type":40},"2023-10-17",{"date":462,"type":40},"2020-05-26",{"date":464,"type":21},"2030-05-26",{"name":46,"class":47},{"id":467,"slug":468,"hasResults":11,"nctId":469,"briefTitle":470,"officialTitle":471,"acronym":472,"eligibilityCriteria":473,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":474,"enrollmentInfo":475,"targetDuration":4,"studyType":22,"phases":477,"briefSummary":478,"conditions":479,"keywords":481,"overallStatus":96,"whyStopped":4,"lastUpdateSubmitDate":341,"lastUpdatePostDateStruct":485,"startDateStruct":486,"completionDateStruct":488,"leadSponsor":490,"locationsCount":491},"100389321","fch-vs-fdg-petct-in-detection-of-lesions-in-patients-with-multiple-myeloma-mim-100389321","NCT04349358","FCH vs FDG PET\u002FCT in Detection of Lesions in Patients With Multiple Myeloma (MIM)","18F-Fluorocholine (FCH) Versus 18F-Fluorodesoxyglucose (FDG) PET\u002FCT in Detection of Lesions in Patients With Multiple Myeloma","MIM","Inclusion Criteria:\n\n* Patient with initial diagnosis of multiple myeloma has just been established\n* Therapeutic indication and eligible for a HSC autograft (if the HSC autograft could not be performed, the patient will still be retained in the study).\n* Status ECOG 0, 1 or 2\n* Age ≥ 18 and \\\u003C 75 ans years\n* Effective contraception for women\n* Informed consent signed\n* Patient able to lie flat for 30 minutes\n* Patient affiliated to a social security scheme\n\nExclusion Criteria:\n\n* Patient diagnosed with a diagnosis of MGUS (Monoclonal Gammapathy of Undetermined Significance = monoclonal gammopathy of undetermined significance), indolent myeloma (\"smoldering myeloma\"), non-secreting myeloma or recurrent myeloma,\n* Patient already under treatment for myeloma.\n* Patient not eligible for intensive treatment followed by a HSC autograft.\n* Patient with concomitant neoplasia\n* Patient with a history of hematological or solid neoplasia, except if it is a basal cell carcinoma of the skin or an adenocarcinoma in situ of the uterine cervix.\n* Patient with a history of sarcoidosis\n* Uncontrolled diabetes.\n* Patient treated with long-term corticosteroids\n* Patient being treated with hematopoietic growth factors\n* Patient in sepsis.\n* Claustrophobic patient.\n* Refusal of patient consent.\n* Pregnant or lactating woman.\n* Women of childbearing potential without effective contraception.\n* Person deprived of liberty or under guardianship\n* Impossibility to submit to the medical follow-up of the trial for geographic, social or psychological reasons.\n* History of allergic reaction attributed to 18F-fluorodeoxyglucose or to 18F-fluorocholine.","75 Years",{"count":476,"type":21},38,[59],"Hybrid positron emission tomography\u002Fcomputed tomography (PET\u002FCT) has now become available to detect tumors in patients with multiple myeloma. The radioactive glucose 18F-fluorodeoxyglucose (FDG) is the most widely used tracer but findings suggest that PET\u002FCT reveal more lesions when using FCH.\n\nIn this study, FDG is compared with a more recent metabolic tracer, 18F-fluorocholine (FCH), for the detection of multiple myeloma lesions at time of initial extension assessment.\n\nThe principal objective of this sudy is to compare the number of suspected hypermetabolic foci of myeloma detected by 18F-fluorocholine PET and by 18F-fluorodeoxyglucose PET during the initial extension assessment.",[480],"Multiple Myeloma",[482,483,484],"PET\u002FCT","FDG","Fluorocholine (18F) FCH",{"date":460,"type":40},{"date":487,"type":40},"2020-12-15",{"date":489,"type":21},"2030-12-15",{"name":46,"class":47},3,""]